This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The first patients have enrolled in a platform clinical trial, called REVOLUTION, testing combination immunotherapy in patients with metastatic pancreatic cancer. The study uses an innovative design to test multiple combination therapies in parallel.
CRI's free and live online event for patients and caregivers covering cancer immunotherapy, clinical trials, and cancer care disparities takes place Oct. 7-8, 2021.
CRI’s free virtual event to connect U.S. Hispanic cancer patients and caregivers with leading cancer experts to discuss breakthroughs in immunotherapy, patient successes, and clinical trials, will be held on September 16, 2021, at 2 p.m. ET
New CRI health equity program supports young Black, Hispanic, and Latino scientists in the fields of immunology and immuno-oncology at top academic research institutions
The Cancer Research Institute awarded $28.5 million to scientists at 43 institutions in 8 countries who are advancing lifesaving research in immunology and cancer immunotherapy during its 2021 funding cycle.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).